Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05914441

Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry

REPTT is an observational, prospective, multi-country, multicentre and non-interventional registry in which at least 300 patients with Thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal will be evaluated.

The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Purpura, Thrombocytopenic Blood Coagulation Disorders Blood Platelet Disorders Cytopenia Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhage Immune System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Purpura Purpura, Thrombotic Thrombocytopenic Signs and Symptoms Skin Manifestations Thrombocytopenia Thrombophilia Thrombotic Microangiopathies

Age range

Up to 99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Universitario Virgen del Rocío, Seville, Andalusia, Spain

Loading trial locations.

About this study

TTP is a rare life-threatening haematological disease characterised by thrombotic microangiopathy (TMA) with an average annual prevalence of approximately 10 cases/million people worldwide and an annual incidence between 1.5 and 6.0 cases per million according to different studies conducted in France, the United States and in the United Kingdom. In Spain the incidence is 2,67 cases / million population per year.

Acute TTP episodes cause sequelae like vascular disease or kidney damage along with other symptoms more subtle like small neurocognitive deficits and myocardial infarction.

Thus, prompt resolution of acute episodes along with a better understanding of the cardiac abnormalities may allow to prevent further complications, to develop targeted rehabilitation techniques for TTP patients and to improve their quality of life.

This project will collect a big database capable of providing better answers to questions related with treatment efficacy, associated morbidity and mortality, and the possible neurocognitive and cardiac sequelae derived from relapses and acute episodes. Additionally, this project will be linked to obtaining biological samples for a serum and DNA library from patients with TTP.

Patients will be recruited by medical researchers specialized in haematology or by other investigators specialized in thrombotic microangiopathies disease management. This recruitment will be performed in a competitive manner. The collection period will be at least 3 years with the possibility of extending it.

REPTT aims to evaluate new scores and prognostic factors of morbidity and mortality in TTP patients.

The final aim is to establish guidelines and recommendation to improve the global management, diagnosis and treatment of patients with TTP in real-life.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with diagnosis of TTP according to International Consensus criteria from centres in Spain and Portugal.
  • Patients that voluntarily sign the informed consent. For subjects unable to provide informed consent, a fully recognized medical authority may be used according to local laws.
  • Patients between 0 to 99 years old at the time of diagnosis.

Note: Decision was taken to treat the patient with an specific treatment prior and independently of patient inclusion in this non interventional study.

Exclusion criteria

  • Inability to comply with study procedures and follow-up exams.
  • Patients with any type of alteration that compromises their ability to grant written informed consent.
  • Patients that do not consent to participate in the study and do not sign informed consent.
  • Patients that do not meet the criteria previously mentioned for TTP.

Treatment and study plan

Standard clinical practice

Other

The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.

Primary outcomes

  1. Incidence of TTP in Spain/Portugal

    Time frame: Throughout the study period, calculated for the 3 years of expected duration.

    Number of patients diagnosed with TTP and enrolled in the registry per year

  2. Morbidity of TTP in Spain/Portugal

    Time frame: Throughout the study period, calculated for the 3 years of expected duration.

    Percentage of patients diagnosed with TTP and enrolled in the registry among spanish / portuguese population per year

  3. Mortality of TTP in Spain/Portugal

    Time frame: Throughout the study period, calculated for the 3 years of expected duration.

    Percentage of patients diagnosed with TTP and enrolled in the registry per year who died due to the disease

Secondary outcomes

  1. Clinical response to treatment rate

    Time frame: Throughout the study period, approximately 3 years per patient

    Defined as sustained normalization of platelet counts above the lower limit of the established reference range and of lactate dehydrogenase (LDH) after cessation of plasma exchange. The number of patients that achieved clinical response and their frequency will be reported.

  2. TTP Clinical remission rate

    Time frame: Throughout the study period, approximately 3 years per patient

    Defined as a clinical response after cessation of plasma exchange, maintained for > 30 days. The number of patients that achieved clinical remission and their frequency will be reported

  3. TTP Exacerbation rate

    Time frame: Throughout the study period, approximately 3 years per patient

    Defined as a reduction in platelet count to below the lower limit of the established reference range, an increased LDH level, and the need to restart plasma exchange within 30 days of the last plasma exchange after a clinical response to plasma exchange. The number of patients with exacerbations and their frequency will be reported

  4. TTP Relapse rate

    Time frame: Throughout the study period, approximately 3 years per patient

    Defined as a fall in platelet count to below the lower limit of the established reference range, with or without clinical symptoms, > 30 days after stopping of plasma exchange for an acute TTP episode, requiring reinitiation of therapy. This is usually associated with a new increase in the LDH level. The number of patients with relapse and their frequency will be reported.

  5. Refractory TTP rate

    Time frame: Throughout the study period, approximately 3 years per patient

    defined as persistent thrombocytopenia, lack of a sustained platelet count increment or low platelet counts and a persistently raised LDH level despite five plasma exchanges 44 and steroid treatment. The number of patients with refractory TTP and their frequency will be reported.

  6. Time-to-response (TTR)

    Time frame: Throughout the study period, approximately 3 years per patient

    Defined as the time from the date of first administration of treatment until the date of clinical response. Patients who die, are lost to follow-up, or reach the time point of analysis without a known record of response will have the TTR censored at the date of death, last assessment or last contact of a follow-up, whichever occurs last. Patients who received a new treatment for TTP whatever the type of treatment before disease response will be censored at the start date of this new treatment. The cumulative incidence of TTR will be estimated by the method of Kaplan-Meier.

  7. Duration of response (DoR)

    Time frame: Throughout the study period, approximately 3 years per patient

    DoR will be calculated among those patients that achieve a clinical response from the time that measurement criteria are first met until the date of exacerbation, relapse, appearance of refractory TTP or death by any cause. Patients who are lost to follow-up, or reach the time point of analysis without a known record of TTP recurrence or death will have the DoR censored at the date of last assessment or last contact of a follow-up, whichever occurs last. Patients who received a new treatment for TTP, whatever the type of treatment, will be censored at the start date of this new treatment.

  8. Relapse-free survival (RFS)

    Time frame: Throughout the study period, approximately 3 years per patient

    RFS will be calculated from the date of first administration of treatment until the date of TTP relapse or the date of death due to any cause. Patients who are lost to follow-up, or reach the time point of analysis without a known record of relapse or death will have the RFS censored at the date of last assessment or last contact, whichever occurs last. Patients who received a new treatment for TTP, whatever the type of treatment, before disease relapse or death will be censored at the start date of this new treatment. The cumulative incidence of relapse will be estimated by the method of Kaplan-Meier

  9. Overall survival (OS)

    Time frame: Throughout the study period, approximately 3 years per patient

    OS will be calculated from the date of the first episode recorded until the date of death due to any cause. Patients who are lost to follow-up or reach the time point of analysis without a known record of death will have the OS censored at the date of last contact. The cumulative incidence of OS will be estimated by the method of Kaplan-Meier.

  10. Frequency of serious adverse events (SAEs)

    Time frame: Throughout the study period, approximately 3 years per patient

    Percentage of patients who experience SAEs during the study

  11. Rate of complications associated with plasma exchange treatment

    Time frame: Throughout the study period, approximately 3 years per patient

    Percentage of patients who experience complications associated with plasma exchange

  12. Frequency of complications associated with plasma exchange treatment

    Time frame: Throughout the study period, approximately 3 years per patient

    Number of complications associated with plasma exchange per TTP event

Study contacts

Contact information is provided by the study sponsor or research team.

Contact person Designated by the Sponsor

CONTACT

[email protected]

+34934344412

Sponsors and collaborators

Lead sponsor

Fundación Española de Hematología y Hemoterapía

Other

Registry information

Official study title

Development Of Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry (REPTT): A Study Proposal Of The Spanish Society Of Hematology And Hemotherapy (SEHH) Whit The Portuguese Society Of Hematology (SPH)

Acronym: RE-PTT

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jun 22, 2023
Registry last updated
May 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.